drugset / Trial / NCT07140393
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.
Timeline
- Start
- 2025-10-28
- Primary completion
- 2027-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | HRS-4508 | Unknown | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |